Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2126
Keros Therapeutics
KROS
$223M
| $1.96M | ﹤0.01% |
+146,600
| New | +$1.98M |
2025 Q2
0 quarters
|
|
2127
Agilon Health
AGL
$1.44B
| $1.96M | ﹤0.01% |
34,000
-17,640
| -34% | -$1.41M |
2024 Q3
3 quarters
|
|
2128
Editas Medicine
EDIT
$375M
| $1.95M | ﹤0.01% |
888,400
-144,565
| -14% | -$237K |
2024 Q4
2 quarters
|
|
2129
Semtech
SMTC
$16.1B
| $1.95M | ﹤0.01% |
43,216
+30,200
| +232% | +$1.07M |
2024 Q3
3 quarters
|
|
2130
Assembly Biosciences
ASMB
$414M
| $1.95M | ﹤0.01% |
107,521
-5,790
| -5% | -$76.4K |
2017 Q1
33 quarters
|
|
2131
Enerflex
EFXT
$3.36B
| $1.94M | ﹤0.01% |
246,300
+32,700
| +15% | +$234K |
2023 Q1
9 quarters
|
|
2132
HUTCHMED
HCM
$2.35B
| $1.94M | ﹤0.01% |
129,000
-6,200
| -5% | -$90.6K |
2022 Q2
12 quarters
|
|
2133
AXIS Capital
AXS
$7.12B
| $1.94M | ﹤0.01% |
18,700
-20,000
| -52% | -$1.99M |
2014 Q2
44 quarters
|
|
2134
iShares Core MSCI Total International Stock ETF
IXUS
$58.5B
| $1.94M | ﹤0.01% |
25,100
+300
| +1% | +$21.9K |
2024 Q4
2 quarters
|
|
2135
Lightpath Technologies
LPTH
$624M
| $1.94M | ﹤0.01% |
629,347
-20,998
| -3% | -$52.1K |
2019 Q3
23 quarters
|
|
2136
DELISTED
Integral Ad Science
IAS
| $1.93M | ﹤0.01% |
232,300
-207,700
| -47% | -$1.58M |
2022 Q2
12 quarters
|
|
2137
Zumiez
ZUMZ
$216M
| $1.92M | ﹤0.01% |
144,900
+14,900
| +11% | +$188K |
2023 Q4
6 quarters
|
|
2138
Maui Land & Pineapple Co
MLP
$293M
| $1.92M | ﹤0.01% |
105,549
+900
| +0.9% | +$14.6K |
2014 Q2
44 quarters
|
|
2139
Eagle Bancorp
EGBN
$859M
| $1.9M | ﹤0.01% |
97,680
+39,980
| +69% | +$742K |
2024 Q1
5 quarters
|
|
2140
Liberty Live Group Series A
LLYVA
$8.79B
| $1.9M | ﹤0.01% |
23,900
-39,200
| -62% | -$2.85M |
2024 Q4
2 quarters
|
|
2141
Five Star Bancorp
FSBC
$1.05B
| $1.9M | ﹤0.01% |
66,500
-8,700
| -12% | -$239K |
2023 Q1
9 quarters
|
|
2142
Village Farms International
VFF
$323M
| $1.89M | ﹤0.01% |
1,722,066
+759,013
| +79% | +$672K |
2022 Q2
12 quarters
|
|
2143
Chesapeake Utilities
CPK
$3.28B
| $1.89M | ﹤0.01% |
+15,750
| New | +$1.98M |
2025 Q2
0 quarters
|
|
2144
Laird Superfood
LSF
$31.1M
| $1.89M | ﹤0.01% |
300,500
+25,200
| +9% | +$157K |
2022 Q1
13 quarters
|
|
2145
Granite Construction
GVA
$5.03B
| $1.89M | ﹤0.01% |
20,200
-3,700
| -15% | -$312K |
2025 Q1
1 quarter
|
|
2146
Allogene Therapeutics
ALLO
$446M
| $1.89M | ﹤0.01% |
1,670,012
+113,312
| +7% | +$151K |
2022 Q4
10 quarters
|
|
2147
DELISTED
Inozyme Pharma
INZY
| $1.88M | ﹤0.01% |
470,500
-93,954
| -17% | -$233K |
2022 Q1
13 quarters
|
|
2148
Sight Sciences
SGHT
$462M
| $1.88M | ﹤0.01% |
455,026
-152,251
| -25% | -$508K |
2023 Q2
8 quarters
|
|
2149
CorMedix
CRMD
$576M
| $1.88M | ﹤0.01% |
+152,200
| New | +$1.68M |
2025 Q2
0 quarters
|
|
2150
Flexible Solutions
FSI
$77.7M
| $1.87M | ﹤0.01% |
386,442
-4,203
| -1% | -$17.6K |
2015 Q2
40 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.